The group's principle activities include discovering, developing, and commercializing new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. The group also provides CancerTYPE ID(SM), H/I(SM) and MGI(SM). The group operates from United States.
